JAMA Oncology 'Under Review': What Each Status Means and When to Expect a Decision

Before the paper reaches external reviewers, a JAMA Network deputy editor at JAMA Oncology evaluates whether the clinical-oncology significance warrants JAMA Oncology's selective editorial slots. With 2200+ submissions per year and a 6 percent acceptance rate, roughly 85 to 90 percent of submissions are rejected at this stage within 1 to 3 weeks. A desk rejection most often means the deputy editor concluded that the work would fit better at a sister JAMA Network title (JAMA Network Open, JAMA) or that the broad-clinical-oncology audience appeal is uncertain.

The JAMA Network editorial office confirms files are complete: manuscript with figures embedded, supplementary information separate, reporting checklists where applicable (CONSORT for clinical trials, STROBE for observational oncology studies, PRISMA for systematic reviews, REMARK for tumor-marker prognostic studies), cover letter directed to the editor, conflict-of-interest declarations, ethics-statement documentation, IRB approvals for human-subjects research, trial-registration documentation (JAMA Network requires registered clinical trials), and statistical analysis plan for clinical-trial submissions.

The deputy editor reads the paper and evaluates clinical-oncology significance, novelty over the existing literature, basic-quality threshold for JAMA Oncology, and broad-clinical audience fit. This is the highest-risk point: many papers are rejected here without external review.

In parallel with the deputy editor's primary read, clinical-trial submissions are routed to JAMA Network in-house statistical reviewers who evaluate trial design, pre-specification compliance, statistical methods, and reporting completeness. This statistical-review stage runs alongside the external reviewer recruitment and adds rigor that contributes to JAMA Oncology's reputation for methodological discipline. The statistical reviewer can flag issues that result in revision requests independent of the external reviewer reports.

JAMA Network deputy editors at JAMA Oncology typically invite 2 to 3 external reviewers, with two reports standard and three common for interdisciplinary work. The recruitment window can take 7 to 14 days because clinical-oncology reviewers with topic-matched expertise are scarce. Finding qualified, available reviewers is often the biggest source of delay.

Once reviewers agree to review, the typical JAMA Oncology peer-review cycle lasts 2 to 3 weeks per reviewer. Reviewers are asked to evaluate clinical-decision impact, trial design and rigor, statistical methodology, and reproducibility. Reviewer reports for JAMA Oncology tend to be thorough; 2000 to 4000 word reports are typical for primary research papers.

After reports return, the deputy editor synthesizes them and consults with statistical reviewers for clinical-trial papers before issuing a decision. Editorial decision synthesis takes 1 to 2 weeks per JAMA Network editorial guidance.

• Rejection within 1 to 3 days: Administrative issue or immediate scope mismatch.

• Rejection within 1 to 3 weeks: Deputy editor desk rejection. Most rejections happen here.

• Still Under Review after 4 weeks: Strong signal. Paper passed the steepest JAMA Network filter.

• Still Under Review after 10 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the submission portal is appropriate.

• Status changes to "Reports Received": Reports are in; expect a decision within 1 to 2 weeks.

This is the most common anxiety we hear from JAMA Oncology authors during the active editorial window. The honest answer: no, 6 weeks at Under Review means your paper passed the deputy editor desk screen (which itself can take 1 to 3 weeks) and is now in active external peer review. JAMA Oncology's reviewer-assignment plus reviewer-response stages typically span 3 to 5 weeks combined.

Most reviewer-driven delays come from reviewer-recruitment timing for clinical-oncology specialists rather than slow reviews. If the portal still says Under Review at the 8-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the deputy editor granted it. This is normal practice at JAMA Network.

During the 6-to-8-week window, the useful distinction is administrative versus scientific urgency. A short portal message is reasonable if you need to disclose a new trial-registration correction, ethics update, related publication, meeting embargo conflict, or material data error. A general "any update?" note is better held until week 8 because the most likely bottleneck is a reviewer extension or statistical-review synthesis, not a missing action from the author.

If your JAMA Oncology paper is rejected after review, the natural cascade depends on what the reviewers and deputy editor cited:

JAMA Network Open is the most natural JAMA Network cascade because JAMA Network supports manuscript-transfer where the receiving editor can request reviewer reports from JAMA Oncology, preserving substantial peer-review work. JAMA Network Open has a broader scope and an open-access publishing model. The transfer process takes 5 to 10 days.

Journal of Clinical Oncology (JCO) is the ASCO cascade option for clinical-oncology trial papers. ASCO operates independently; reports do not transfer, but JCO editors may recognize JAMA Network reviewer reports informally. JCO's review focus is similar but emphasizes ASCO-treatment-guideline implications.

Annals of Oncology is the ESMO cascade option for European-oncology-focused work. ESMO operates independently with its own reviewer pool.

Cancer Discovery (AACR) is a cascade option for translational-oncology papers where the basic-science mechanism is stronger than the clinical-trial focus. AACR operates independently from JAMA Network.

JAMA Network asks reviewers at JAMA Oncology to evaluate four things specifically. The table below maps each to actionable preparation.

In our pre-submission work with JAMA Oncology manuscripts, three patterns generate the most consistent reviewer concerns we see at JAMA Oncology. The recurring issue is not only whether the trial, cohort, or oncology analysis is well run. It is whether the Key Points, first table, and statistical appendix let a deputy editor and statistical reviewer see the same clinical decision without extra explanation.

CONSORT-compliance gaps surface as reviewer requests for clarification. When CONSORT checklist items are incomplete or trial-pre-registration alignment is unclear, JAMA Network in-house statistical reviewers consistently flag for revision. The strongest revisions add complete CONSORT documentation with pre-registration alignment and explicit deviation explanations.

Check your JAMA Oncology reporting package →

Statistical analysis plan under-documented. When the pre-specified statistical analysis plan is thin or post-hoc analyses are not clearly distinguished from pre-specified analyses, JAMA Network statistical reviewers consistently request expanded methods documentation. The strongest revisions add complete pre-specified analysis plans as supplementary material.

Check your statistical methods and SAP alignment →

Clinical-decision impact under-stated in framing. When the abstract and discussion do not clearly establish the clinical decision that would change, deputy editors and reviewers flag general-clinical-interest concerns. The strongest manuscripts frame the abstract around the specific oncology decision the paper affects.

Check your oncology decision framing →

We have reviewed 50+ manuscripts targeting JAMA Oncology, Journal of Clinical Oncology, Annals of Oncology, Lancet Oncology, and JAMA Network Open. The JAMA Oncology misses tend to appear before the Methods section: the Key Points name an outcome but not the oncology decision, the abstract reports statistical significance without clinical actionability, or the first table makes subgroup balance and endpoint hierarchy harder to audit than it should be. Those are fixable before submission, and they matter because JAMA Network combines clinical editor review with statistical review.

In our pre-submission review work across clinical-oncology and general-medical targets, we see five recurring preventable risks: incomplete trial-registration alignment, weak explanation of post-hoc analyses, unclear clinical-decision framing, missing patient-flow or subgroup transparency, and related-paper disclosure that appears late instead of at upload. This is an internal Manusights review sample, not a JAMA Network outcome dataset, so we use it to identify preventable manuscript risks rather than to estimate acceptance probability.

Source limitation: official guidance explains JAMA Network author rules, timing signals, and reporting requirements, but it does not show private deputy-editor notes, statistical-review comments, or the reason a specific manuscript is still in the portal. That is why this page separates public status interpretation from manuscript-specific readiness signals.

Our strongest JAMA Oncology pre-submission fixes are usually small but consequential: rewrite the Key Points around the treatment, screening, diagnostic, survivorship, or policy decision; add a one-paragraph statistical-analysis audit to the cover letter; move SAP and checklist files into a clearly labeled supplementary package; and make the first response-template outline before reviewer reports arrive. Manusights does not train AI models on customer manuscripts; we do not train on private author files.

The 60-day money-back guarantee applies to eligible paid manuscript reviews. That combination lets authors pressure-test the paper without turning the manuscript into a public training artifact.

This page was created from JAMA Network's public author guidance at Jamanetwork author instructions, JAMA Network editorial-process documentation, JAMA Oncology submission-and-acceptance data (2200+ annual submissions, 6 percent acceptance), and Manusights pre-submission review experience with JAMA Oncology-targeted manuscripts. Numeric claims about desk-decision and review-time windows are sourced to JAMA Network editorial guidance.

For the JAMA Network oncology landscape beyond JAMA Oncology, see JAMA Network Open (broader open-access), JAMA (top general-medicine), JAMA Internal Medicine (internal medicine focus), and sister oncology titles (JCO, Annals of Oncology, Lancet Oncology, Cancer Discovery).

The choice across these titles depends on whether the central contribution is top-clinical-oncology (JAMA Oncology), broad-clinical-medicine (JAMA), or specialty-oncology (JCO, Annals of Oncology). For technical issues during JAMA Network submission, the submission portal handles most queries via the manuscript record.

Reviewers at JAMA Oncology typically draw from one clinical oncologist and one methodologist or statistician (in addition to the JAMA Network in-house statistical reviewer for clinical trials). Preparing a response template that addresses both perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the JAMA Oncology clinical-impact-plus-statistical-rigor bar before submission, our JAMA Oncology pre-submission diagnostic flags the CONSORT-compliance gaps and statistical-methodology weaknesses most likely to surface in reviewer reports.